Global Information
회사소개 | 문의 | 비교리스트

월경곤란증 : 시장 인사이트, 역학, 시장 예측(2030년)

Dysmenorrhea - Market Insight, Epidemiology and Market Forecast -2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 11월 상품 코드 968231
페이지 정보 영문 185 Pages
가격
US $ 6,950 ₩ 7,792,000 PDF (Single User License)
US $ 13,900 ₩ 15,584,000 PDF (Site License)
US $ 20,850 ₩ 23,377,000 PDF (Global License)


월경곤란증 : 시장 인사이트, 역학, 시장 예측(2030년) Dysmenorrhea - Market Insight, Epidemiology and Market Forecast -2030
발행일 : 2020년 11월 페이지 정보 : 영문 185 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

2017년 월경곤란증 유병자 총수는 주요 7개국에서 134,524,953명이 되었습니다. 미국은 2017년에 58,670,651명이 되었습니다(주요 7개국 중에서 최다).

유럽 5개국 중에서 월경곤란증 유병자수가 가장 많았던 것은 독일로, 2017년에는 13,122,996명이고 2030년까지 증가할 것으로 추정됩니다. 스페인은 유병자수가 가장 적고, 2017년에는 445,364명이었습니다.

주요 7개국 중 일본은 2017년에 원발성 및 연발성 월경곤란증이 각각 18,442,399명과 2,410,771명이 되었습니다.

미국, 유럽 5개국(독일, 스페인, 이탈리아, 프랑스, 영국) 및 일본 7개 주요 시장의 월경곤란증(Dysmenorrhea) 시장에 대해 상세하게 설명하고, 질환 배경과 개요, 미충족 수요, 각국의 역학, 치료법 등에 관한 정보를 제공합니다.

목차

제1장 중요한 인사이트

제2장 월경곤란증 주요 요약

제3장 SWOT 분석

제4장 역학과 시장 조사 방법

제5장 월경곤란증 : 시장 점유율(%) 분포 개요 - 국가별

제6장 월경곤란증 : 질환 배경과 개요

  • 월경곤란증 종류
  • 위험인자
  • 징후와 증상
  • 병태생리학
  • 진단
  • 진단 알고리즘
  • 진단 가이드라인
    • National Institute for Health and Care Excellence(NICE) 가이드라인

제7장 역학과 환자 인구

  • 주요 조사 결과
  • 가정과 이론적 근거 : 주요 7개국
  • 역학 시나리오 : 주요 7개국
    • 주요 7개국의 월경곤란증 유병자 총수와 그 종류(원발성 및 연발성 월경곤란증)
    • 주요 7개국의 월경곤란증 발증자 총수와 그 종류(원발성 및 연발성 월경곤란증)
    • 주요 7개국의 월경곤란증 유병자수 : 중증도별
    • 주요 7개국의 원발성 및 연발성 월경곤란증 치료자수
  • 미국의 역학
    • 미국의 월경곤란증 유병자 총수와 그 종류(원발성 및 연발성 월경곤란증)
    • 미국의 월경곤란증 발증자 총수와 그 종류(원발성 및 연발성 월경곤란증)
    • 미국의 월경곤란증 유병자수 : 중증도별
    • 미국의 원발성 및 연발성 월경곤란증 치료자수
  • 유럽 5개국의 역학
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 영국
  • 일본

제8장 현재 치료법

  • 약리학적 치료
    • NSAID
    • 호르몬 피임약
    • 고나도트로핀 방출 호르몬(GnRH) 유사체
  • 수술
    • 자궁(자궁적출술) 및 난소(난소적출술) 제거
    • 복강경하 자궁신경절제 및 복강경하 전천골신경절제술
  • 비약리학적 치료
    • 경피적 전기신경자극(TENS)
    • 지지요법
  • 치료 알고리즘
  • 월경곤란증 가이드라인
    • American College of Obstetricians and Gynecologists(ACOG) 추천사항
    • NICE 추천사항 : 자궁내막증(2017년)
    • 일본산부인과학회(JSOG) 및 일본산부인과학회(JAOG) 2017년판
    • 자궁내막증 관련 통증에 관한 European Society of Human Reproduction and Embryology(ESHRE) 가이드라인 : 2013년

제9장 미충족 수요

제10장 환자 여정

제11장 월경곤란증 임상시험의 주요 엔드포인트

제12장 시판약

  • 경쟁
  • Orilissa(Elagolix): AbbVie/Neurosciences Biosciences
    • 제품 설명
    • 규제 마일스톤
    • 기타 개발 활동
    • 중요한 임상시험
    • 진행중인 임상시험 활동
  • Jemina Tablets(levonorgestrel - ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical
  • Visanne(Dinagest): Mochida/Bayer Schering Pharma AG
    • 중요한 임상시험

제13장 새로운 치료제

  • Yselty(Linzagolix; OBE2109): ObsEva
    • 제품 설명
    • 기타 개발 활동
    • 임상 개발
    • 안전성과 유효성
  • Relugolix(TAK-385): Myovant Sciences/Takeda
  • Pure Femme Tablets: Pure Green
  • FSN-013(Estetrol/Drospirenone): Fuji Pharma
  • NS-580: Nippon Shinyaku

제14장 월경곤란증 치료의 컨조인트 분석

제15장 월경곤란증 : 주요 7개 시장 분석

  • 주요 조사 결과
  • 시장 전망

제16장 주요 7개국의 시장 규모

  • 주요 7개국의 월경곤란증 전체 시장 규모
  • 주요 7개국의 월경곤란증 전체 시장 규모 : 치료별

제17장 미국의 시장 규모

  • 미국의 월경곤란증 전체 시장 규모

제18장 유럽 5개국의 시장 규모

  • 독일의 시장 규모
    • 독일의 월경곤란증 전체 시장 규모
  • 프랑스의 시장 규모
  • 이탈리아의 시장 규모
  • 스페인의 시장 규모
  • 영국의 시장 규모
    • 영국의 월경곤란증 전체 시장 규모

제19장 일본의 시장 규모

  • 일본의 월경곤란증 전체 시장 규모

제20장 월경곤란증 치료의 시장 접근과 의료비 상환

제21장 시장 성장 촉진요인

제22장 시장 장벽

제23장 부록

  • 참고문헌
  • 보고서 조사 방법
  • DelveInsight 서비스 내용

제24장 면책사항

제25장 DelveInsight 소개

KSM 20.11.18

List of Tables

  • Table 1 Summary of Dysmenorrhea Market, Epidemiology, and Key Events (2017-2030)
  • Table 2 Stages of Endometriosis
  • Table 3 Differential Diagnosis of Dysmenorrhea
  • Table 4 NICE Recommendations
  • Table 5 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
  • Table 6 Total Prevalent Cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
  • Table 7 Total Diagnosed cases of Dysmenorrhea, and its types (Primary dysmenorrhea, and Secondary dysmenorrhea) in the 7MM (2017-2030)
  • Table 8 Severity-specific Prevalent Cases of Primary dysmenorrhea in the 7MM (2017-2030)
  • Table 9 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the 7MM (2017-2030)
  • Table 10 Total Treated cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
  • Table 11 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
  • Table 12 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
  • Table 13 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United States (2017-2030)
  • Table 14 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United States (2017-2030)
  • Table 15 Total Treated cases of Primary and Secondary Dysmenorrhea in the United States (2017-2030)
  • Table 16 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
  • Table 17 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
  • Table 18 Severity-specific Prevalent Cases of Primary dysmenorrhea in Germany (2017-2030)
  • Table 19 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Germany (2017-2030)
  • Table 20 Total Treated cases of Primary and Secondary Dysmenorrhea in Germany (2017-2030)
  • Table 21 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
  • Table 22 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
  • Table 23 Severity-specific Prevalent Cases of Primary dysmenorrhea in France (2017-2030)
  • Table 24 Severity-specific Prevalent Cases of Secondary dysmenorrhea in France (2017-2030)
  • Table 25 Total Treated cases of Primary and Secondary Dysmenorrhea in France (2017-2030)
  • Table 26 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
  • Table 27 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
  • Table 28 Severity-specific Prevalent Cases of Primary dysmenorrhea in Italy (2017-2030)
  • Table 29 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Italy (2017-2030)
  • Table 30 Total Treated cases of Primary and Secondary Dysmenorrhea in Italy (2017-2030)
  • Table 31 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
  • Table 32 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
  • Table 33 Severity-specific Prevalent Cases of Primary dysmenorrhea in Spain (2017-2030)
  • Table 34 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Spain (2017-2030)
  • Table 35 Total Treated cases of Primary and Secondary Dysmenorrhea in Spain (2017-2030)
  • Table 36 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
  • Table 37 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
  • Table 38 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United Kingdom (2017-2030)
  • Table 39 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United Kingdom (2017-2030)
  • Table 40 Total Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom (2017-2030)
  • Table 41 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
  • Table 42 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
  • Table 43 Severity-specific Prevalent Cases of Primary dysmenorrhea in Japan (2017-2030)
  • Table 44 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Japan (2017-2030)
  • Table 45 Total Treated cases of Primary and Secondary Dysmenorrhea in Japan (2017-2030)
  • Table 46 Marketed Key Cross
  • Table 47 Orilissa; Clinical Trial Description, 2020
  • Table 48 Yselty (Linzagolix; OBE2109) Clinical Trial Description, 2020
  • Table 49 Relugolix (TAK-385); Clinical Trial Description, 2020
  • Table 50 Pure Femme Tablets, Clinical Trial Description, 2020
  • Table 51 FSN-013; Clinical Trial Description, 2020
  • Table 52 NS-580, Clinical Trial Description, 2020
  • Table 53 7MM Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 54 7MM Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 55 Total United States Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 56 United States Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 57 Germany Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 58 Germany Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 59 France Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 60 France Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 61 Italy Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 62 Italy Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 63 Spain Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 64 Spain Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 65 United Kingdom Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 66 United Kingdom Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)
  • Table 67 Japan Market Size of Dysmenorrhea, in USD Million (2017-2030)
  • Table 68 Japan Market Size of Dysmenorrhea by Therapies, in USD Million (2017-2030)

List of Figures

  • Figure 1 Dysmenorrhea SWOT Analysis
  • Figure 2 Dysmenorrhea
  • Figure 3 Types of Dysmenorrhea
  • Figure 4 Endometriosis
  • Figure 5 Uterine fibroids
  • Figure 6 Adenomyosis
  • Figure 7 Risk Factors
  • Figure 8 Symptoms
  • Figure 9 Pathophysiology of Adolescent dysmenorrhea
  • Figure 10 Laparoscopy
  • Figure 11 Hysteroscopy
  • Figure 12 Diagnostic Algorithm
  • Figure 13 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
  • Figure 14 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM (2017-2030)
  • Figure 15 Severity-specific Prevalent Cases of Primary dysmenorrhea in the 7MM (2017-2030)
  • Figure 16 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the 7MM (2017-2030)
  • Figure 17 Total Treated cases of Primary and Secondary Dysmenorrhea in the 7MM (2017-2030)
  • Figure 18 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
  • Figure 19 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States (2017-2030)
  • Figure 20 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United States (2017-2030)
  • Figure 21 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United States (2017-2030)
  • Figure 22 Treated cases of Primary and Secondary Dysmenorrhea in the United States (2017-2030)
  • Figure 23 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
  • Figure 24 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany (2017-2030)
  • Figure 25 Severity-specific Prevalent Cases of Primary dysmenorrhea in Germany (2017-2030)
  • Figure 26 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Germany (2017-2030)
  • Figure 27 Treated cases of Primary and Secondary Dysmenorrhea in Germany (2017-2030)
  • Figure 28 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
  • Figure 29 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France (2017-2030)
  • Figure 30 Severity-specific Prevalent Cases of Primary dysmenorrhea in France (2017-2030)
  • Figure 31 Severity-specific Prevalent Cases of Secondary dysmenorrhea in France (2017-2030)
  • Figure 32 Treated cases of Primary and Secondary Dysmenorrhea in France (2017-2030)
  • Figure 33 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
  • Figure 34 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy (2017-2030)
  • Figure 35 Severity-specific Prevalent Cases of Primary dysmenorrhea in Italy (2017-2030)
  • Figure 36 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Italy (2017-2030)
  • Figure 37 Treated cases of Primary and Secondary Dysmenorrhea in Italy (2017-2030)
  • Figure 38 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
  • Figure 39 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain (2017-2030)
  • Figure 40 Severity-specific Prevalent Cases of Primary dysmenorrhea in Spain (2017-2030)
  • Figure 41 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Spain (2017-2030)
  • Figure 42 Treated cases of Primary and Secondary Dysmenorrhea in Spain (2017-2030)
  • Figure 43 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
  • Figure 44 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom (2017-2030)
  • Figure 45 Severity-specific Prevalent Cases of Primary dysmenorrhea in the United Kingdom (2017-2030)
  • Figure 46 Severity-specific Prevalent Cases of Secondary dysmenorrhea in the United Kingdom (2017-2030)
  • Figure 47 Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom (2017-2030)
  • Figure 48 Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
  • Figure 49 Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan (2017-2030)
  • Figure 50 Severity-specific Prevalent Cases of Primary dysmenorrhea in Japan (2017-2030)
  • Figure 51 Severity-specific Prevalent Cases of Secondary dysmenorrhea in Japan (2017-2030)
  • Figure 52 Treated cases of Primary and Secondary Dysmenorrhea in Japan (2017-2030)
  • Figure 53 Stepwise approach to treat dysmenorrhea
  • Figure 54 Treatments Options for Dysmenorrhea
  • Figure 55 Contraceptive Vaginal Ring
  • Figure 56 Common IUD Types
  • Figure 57 Effects of GnRH antagonists
  • Figure 58 Recommended points for TENS therapy
  • Figure 59 Flowchart for the management of patients with dysmenorrhea.
  • Figure 60 Treatment algorithm for dysmenorrhea.
  • Figure 61 Treatment pathway for women presenting with dysmenorrhea in primary care
  • Figure 62 An endometriosis treatment algorithm
  • Figure 63 Unmet Needs of Dysmenorrhea
  • Figure 64 Patient Journey
  • Figure 65 Market Size of Dysmenorrhea in the 7MM, in USD Million (2017-2030)
  • Figure 66 Market Size of Dysmenorrhea in the 7MM by Therapy, in USD Million (2017-2030)
  • Figure 67 Total Market Size of Dysmenorrhea in the United States, in USD Million (2017-2030)
  • Figure 68 Market Size of Dysmenorrhea in the United States by Therapy, in USD Million (2017-2030)
  • Figure 69 Total Market Size of Dysmenorrhea in Germany, in USD Million (2017-2030)
  • Figure 70 Market Size of Dysmenorrhea in Germany by Therapies, in USD Million (2017-2030)
  • Figure 71 Total Market Size of Dysmenorrhea in France, in USD Million (2017-2030)
  • Figure 72 Market Size of Dysmenorrhea in France by therapies, in USD Million (2017-2030)
  • Figure 73 Total Market Size of Dysmenorrhea in Italy, in USD Million (2017-2030)
  • Figure 74 Market Size of Dysmenorrhea in Italy by Therapies, in USD Million (2017-2030)
  • Figure 75 Total Market Size of Dysmenorrhea in Spain, in USD Million (2017-2030)
  • Figure 76 Market Size of Dysmenorrhea in Spain by therapies, in USD Million (2017-2030)
  • Figure 77 Total Market Size of Dysmenorrhea in the United Kingdom by Therapies, in USD Million (2017-2030)
  • Figure 78 Market Size of Dysmenorrhea in the United Kingdom by Therapies, in USD Million (2017-2030)
  • Figure 79 Total Market Size of Dysmenorrhea in Japan, in USD Million (2017-2030)
  • Figure 80 Market Size of Dysmenorrhea in Japan by Therapy, in USD Million (2017-2030)
  • Figure 81 Market Drivers
  • Figure 82 Market Barriers

DelveInsight's 'Dysmenorrhea-Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Dysmenorrhea, historical and forecasted epidemiology as well as the Dysmenorrhea market trends in the United States, EU-5 (Germany, France, Italy, Spain, and United Kingdom), and Japan.

The dysmenorrhea market report provides current treatment practices, emerging drugs, Dysmenorrhea market share of the individual therapies, current and forecasted Dysmenorrhea market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Dysmenorrhea treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2030

Dysmenorrhea: Disease Understanding and Treatment Algorithm

Dysmenorrhea Overview

Painful menstrual periods in medical term are described as Dysmenorrhea, which is often called as "menstrual cramps" in simpler terms. Dysmenorrhea can be classified into two types: Primary Dysmenorrhea and Secondary Dysmenorrhea. Primary dysmenorrhea is common menstrual cramps related to the normal process of menstruation. These cramps are recurrent and are not due to other diseases. Pain can range from mild to severe, can typically last 12-72 hours, and can be accompanied by nausea and vomiting, fatigue, and even diarrhea. Whereas, in secondary dysmenorrhea the pain is caused by any disorder in the woman's reproductive organs. Pain usually begins earlier in the menstrual cycle and lasts longer than common menstrual cramps. Contrary to the primary dysmenorrhea, in this type pain is not typically accompanied by nausea, vomiting, fatigue, or diarrhea. The most common cause of secondary dysmenorrhea is endometriosis.

Dysmenorrhea is common in women from every age and region; however, certain risk factors which add to the increased risk are smoking, consuming alcohol during their menstrual cycle, being overweight or obese, sexual abuse, Low body mass index, etc.

Dysmenorrhea Diagnosis

The diagnosis for dysmenorrhea involves the doctor analyzing the menstrual history of the patient along with their family history too, followed by conducting tests such as MRI, Ultrasound, and Laparoscopy, etc., if needed.

Dysmenorrhea Treatment

The treatment pattern can be broadly divided into three parts: Pharmacological treatment, surgery and Non- Pharmacological treatment. Pharmacological treatment comprises the use of nonsteroidal anti-inflammatory drugs (NSAIDs), hormonal contraception and Gonadotropin-releasing hormone (GnRH) analogs. Whereas, currently used Non-pharmacological practice includes the use Transcutaneous electrical nerve stimulation (TENS) and Supportive Therapies.

Dysmenorrhea Epidemiology

The Dysmenorrhea epidemiology division provides the insights about historical and current Dysmenorrhea patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Dysmenorrhea epidemiology [segmented as Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea), Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea, Severity-specific Prevalent Cases of Primary dysmenorrhea, Severity-specific Prevalent Cases of Secondary dysmenorrhea, Treated cases of Primary and Secondary Dysmenorrhea] scenario of Dysmenorrhea in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise-Dysmenorrhea Epidemiology

  • In the year 2017, the total prevalent cases of Dysmenorrhea were 134,524,953 in the 7MM. The United States, in 2017, accounted for 58,670,651 cases (the highest number among the 7MM countries).
  • Among the EU-5 countries, the highest number of cases of Dysmenorrhea were in Germany, i.e., 13,122,996 cases in the year 2017, which is estimated to rise by the year 2030.
  • Spain accounted for the least number of prevalent cases, i.e., 445,364 cases in 2017.
  • Among the 7MM, Japan accounted for 18,442,399, and 2,410,771 Primary and Secondary Dysmenorrhea cases, respectively in 2017.

Dysmenorrhea Drug Chapters

Drug chapter segment of the Dysmenorrhea report encloses the detailed analysis of Dysmenorrhea marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Dysmenorrhea clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Dysmenorrhea Emerging Drugs

Relugolix: Myovant Sciences GmbH/ Takeda

Myovant Sciences is developing its potential drug Relugolix, which is a small molecule consumed orally and its mechanism of action includes acting as a GnRH receptor antagonist, for the treatment of uterine fibroids and endometriosis. Relugolix is the most anticipated phase III program for the treatment of endometriosis-associated pain. For this candidate, Takeda has commercial rights for Japan along with some parts of Asia. In other regions, Myovant Sciences holds commercialization rights. Myovant was formed by Takeda and Roivant Sciences in June 2016.

Yselty (Linzagolix; OBE2109): ObsEva

Yselty (previously known as Linzagolixx, OBE2109) by ObsEva is a novel, oral, once-daily, GnRH receptor antagonist with the tagline best-in-class profile. As per the company, the aspect which makes it different from the other marketed GnRH, is that it has the potential to provide effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments.

FSN-013 (Estetrol/ Drospirenone): Fuji Pharma

FSN-013 is a 5th generation combined oral contraceptive drug of Fuji Pharma composed of estetrol (a natural estrogen) and drospirenone. As of now, it has exhibited some of the eye-catching characteristics such as improved bleeding control as compared to other drugs. Along with this, it also has lower lipid impact, and lower interaction among other drugs.

Pure Femme Tablets: Pure Green

Pure Green Pharmaceuticals is an emerging the US-based biotech start-up, at the forefront of research into the therapeutic qualities of cannabis. Currently, a phase II (NCT04091789) clinical trial is in its recruiting stage which is anticipated to include 30 patients.

Products detail in the report…

Dysmenorrhea Market Outlook

Key Findings

According to DelveInsight, Dysmenorrhea market in the 7MM is expected to change in the study period 2017-2030.The therapeutic market of Dysmenorrhea in seven major markets was found to be USD 7,430 million in 2017 which is expected to increase during study period (2017-2030).

The United States Market Outlook

In 2017, the total market size of Dysmenorrhea therapies was found to be USD 4,582 million in the United States which is expected to increase in the study period (2017-2030).

EU-5 Countries: Market Outlook

In 2017, the total market size of Dysmenorrhea therapies was found to be USD 2,071 million in the EU-5 countries which is expected to increase in the study period (2017-2030).

Japan Market Outlook

The total market size of Dysmenorrhea therapies in Japan was found to be USD 777 million in 2017.

Dysmenorrhea Pipeline Development Activities

The drugs which are in pipeline includes:

  • Yselty (Linzagolix; OBE2109): ObsEva: Phase III
  • Relugolix (TAK-385): Myovant Sciences/Takeda: Phase III
  • Pure Femme Tablets: Pure Green: Phase II
  • FSN-013 (Estetrol/ Drospirenone): Fuji Pharma: Phase II

List is not exhaustive, full list and Products detail will be provided in the report…

Pipeline Development Activities

Key Points

  • In October 2019, Myovant Sciences completed the patient recruitment process for its ongoing phase III SPIRIT 1 clinical trial assessing the safety and effectiveness of Relugolix in combination with estradiol and progestin to treat pain in women with endometriosis.
  • In May 2018, Takeda Pharmaceuticals and ASKA Pharmaceutical entered into a licensing agreement to grant ASKA exclusive commercialization right for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan to maximize the product value of Takeda-owned Relugolix.

Dysmenorrhea Drugs Uptake

Among emerging therapies, Relugolix data from SPIRIT 1 and SPIRIT 2 looks promising and expected to garner the highest market share. On a cross-trial basis, efficacy of Relugolix is in line with a high Orilissa dose, but without the same association with hot flushes and bone density loss.

Access and Reimbursement Scenario in Dysmenorrhea Therapies

  • For easy access, Patient Assistance Program (PAP) help patients with limited resources. It is worth noting that, the Company's myAbbVie Assist provides free medicines to qualified patients. Eligible patients are the ones that have been prescribed Orilissa, have limited or no health insurance coverage, live in the United States, and are being treated by a licensed US health care provider on an outpatient basis.
  • Direct healthcare costs for managing endometriosis associated pain and indirect costs to patients, employers, and society due to loss of employment and productivity, are substantial. Dysmenorrhea and endometriosis associated pain, are a significant cost burden for payers in the US healthcare system because hysterectomy-the common curative treatment-is associated with high hospitalization costs. There is a lack of reimbursement policies for most of the therapies; however, by considering the unavailability of effective treatments, the reimbursement of therapies for Dysmenorrhea could be less complicated in the near future.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in Dysmenorrhea domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Dysmenorrhea market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Dysmenorrhea Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Dysmenorrhea, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Dysmenorrhea epidemiology and treatment in the 7MM.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Dysmenorrhea are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Dysmenorrhea market; historical and forecasted is included in the report, covering drug outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Dysmenorrhea market.

Report Highlights:

  • In the coming years, Dysmenorrhea market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Dysmenorrhea R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Dysmenorrhea. Launch of emerging therapies, will significantly impact the Dysmenorrhea market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Dysmenorrhea.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Dysmenorrhea Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Dysmenorrhea Pipeline Analysis
  • Dysmenorrhea Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Dysmenorrhea Report Key Strengths

  • 11 Years Forecast
  • 7MMCoverage
  • Dysmenorrhea Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Dysmenorrhea Report Assessment

  • SWOT Analysis
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Conjoint Analysis
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Dysmenorrhea Market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Dysmenorrhea total market Size as well as market size by therapies across the 7MM during the study period (2017-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Dysmenorrhea market size during the study period (2017-2030)?
  • At what CAGR, the Dysmenorrhea market is expected to grow in the 7MM during the study period (2017-2030)?
  • What would be the Dysmenorrhea market outlook across the 7MM during the study period (2017-2030)?
  • What would be the Dysmenorrhea market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and a subsequent analysis of the associated trends?
  • Dysmenorrhea patient types/ pool where unmet need is more and whether emerging therapies will be able to address the residual unmet need?
  • How emerging therapies are performing on the parameters like efficacy, safety, route of administration (RoA), treatment duration and frequencies based on their clinical trial results?
  • Among the emerging therapies, what are the potential therapies which are expected to disrupt the Dysmenorrhea market?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Dysmenorrhea?
  • What is the historical Dysmenorrhea patient pool in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What would be the forecasted patient pool of Dysmenorrhea in 7 major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Dysmenorrhea?
  • Out of all the 7MM countries, which country would have the highest prevalent population of Dysmenorrhea during the study period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the study period (2017-2030)?
  • What are the various recent and upcoming events which are expected to improve the diagnosis of Dysmenorrhea?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Dysmenorrhea along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Dysmenorrhea in the US, Europe and Japan?
  • What are the Dysmenorrhea marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Dysmenorrhea?
  • How many therapies are developed by each company for the treatment of Dysmenorrhea?
  • How many emerging therapies are in mid stage, and late stage of development for the treatment of Dysmenorrhea?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dysmenorrhea therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dysmenorrhea and their status?
  • What are the key designations that have been granted for the emerging therapies for Dysmenorrhea?
  • What are the global historical and forecasted market of Dysmenorrhea?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Dysmenorrhea market.
  • To understand the future market competition in the Dysmenorrhea market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Dysmenorrhea in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Dysmenorrhea market.
  • To understand the future market competition in the Dysmenorrhea market.

Table of Contents

1. Key Insights

2. Executive Summary of Dysmenorrhea

3. SWOT Analysis

4. Epidemiology and Market Methodology

5. Dysmenorrhea: Market Share (%) Distribution Overview at a Glance: By Country

6. Dysmenorrhea: Disease Background and Overview

  • 6.1. Types of Dysmenorrhea
  • 6.2. Risk Factors
  • 6.3. Signs and Symptoms
  • 6.4. Pathophysiology
  • 6.5. Diagnosis
  • 6.6. Diagnostic Algorithm
  • 6.7. Diagnostic Guidelines
    • 6.7.1. National Institute for Health and Care Excellence (NICE) Guidelines

7. Epidemiology and Patient Population

  • 7.1. Epidemiology Key Findings
  • 7.2. Assumptions and Rationale
  • 7.3. Epidemiology Scenario: 7MM
    • 7.3.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM
    • 7.3.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the 7MM
    • 7.3.3. Severity-specific Prevalent Cases of Dysmenorrhea in the 7MM
    • 7.3.4. Treated cases of Primary and Secondary Dysmenorrhea in the 7MM
  • 7.4. The United States Epidemiology
    • 7.4.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States
    • 7.4.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United States
    • 7.4.3. Severity-specific Prevalent Cases of Dysmenorrhea in the United States
    • 7.4.4. Treated cases of Primary and Secondary Dysmenorrhea in the United States
  • 7.5. EU-5 Epidemiology
  • 7.6. Germany
    • 7.6.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany
    • 7.6.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Germany
    • 7.6.3. Severity-specific Prevalent Cases of Dysmenorrhea in Germany
    • 7.6.4. Treated cases of Primary and Secondary Dysmenorrhea in Germany
  • 7.7. France
    • 7.7.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France…
    • 7.7.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in France
    • 7.7.3. Severity-specific Prevalent Cases of Dysmenorrhea in France
    • 7.7.4. Treated cases of Primary and Secondary Dysmenorrhea in France
  • 7.8. Italy
    • 7.8.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy
    • 7.8.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Italy
    • 7.8.3. Severity-specific Prevalent Cases of Dysmenorrhea in Italy
    • 7.8.4. Treated cases of Primary and Secondary Dysmenorrhea in Italy
  • 7.9. Spain
    • 7.9.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain
    • 7.9.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Spain
    • 7.9.3. Severity-specific Prevalent Cases of Dysmenorrhea in Spain
    • 7.9.4. Treated cases of Primary and Secondary Dysmenorrhea in Spain
  • 7.10. The United Kingdom
    • 7.10.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom
    • 7.10.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in the United Kingdom
    • 7.10.3. Severity-specific Prevalent Cases of Dysmenorrhea in the United Kingdom
    • 7.10.4. Treated cases of Primary and Secondary Dysmenorrhea in the United Kingdom
  • 7.11. Japan Epidemiology
    • 7.11.1. Total Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan
    • 7.11.2. Total Diagnosed Prevalent Cases of Dysmenorrhea and its Types (Primary and Secondary Dysmenorrhea) in Japan
    • 7.11.3. Severity-specific Prevalent Cases of Dysmenorrhea in Japan
    • 7.11.4. Treated cases of Primary and Secondary Dysmenorrhea in Japan

8. Current Treatment Practices

  • 8.1. Pharmacological Treatments
    • 8.1.1. NSAIDs
    • 8.1.2. Hormonal contraception
    • 8.1.3. Gonadotropin-releasing hormone (GnRH) analogs
  • 8.2. Surgery
    • 8.2.1. Removal of the uterus (hysterectomy) and ovaries (oophorectomy)
    • 8.2.2. Laparoscopic uterine nerve ablation and laparoscopic presacral neurectomy
  • 8.3. Non-Pharmacological Treatments
    • 8.3.1. Transcutaneous electrical nerve stimulation (TENS)
    • 8.3.2. Supportive Therapies
  • 8.4. Treatment Algorithms
  • 8.5. Guideline of Dysmenorrhea
    • 8.5.1. American College of Obstetricians and Gynecologists (ACOG) recommendations for Dysmenorrhea and Endometriosis in the Adolescent
    • 8.5.2. NICE Recommendations: Endometriosis (2017)
    • 8.5.3. Japan Society of Obstetrics and Gynecology (JSOG) and Japan Association of Obstetricians and Gynecologists (JAOG) 2017 edition
    • 8.5.4. Guideline of the European Society of Human Reproduction and Embryology (ESHRE) for Endometriosis-associated pain: 2013

9. Unmet Needs

10. Patient Journey

11. Key Endpoints in Dysmenorrhea Clinical Trials

12. Marketed Therapies

  • 12.1. Marketed Key Cross
  • 12.2. Orilissa (Elagolix): AbbVie/ Neurosciences Biosciences
    • 12.2.1. Product Description
    • 12.2.2. Regulatory Milestones
    • 12.2.3. Other Developmental Activities
    • 12.2.4. Pivotal Clinical Trial
    • 12.2.5. Ongoing Clinical Trial Activity
  • 12.3. Jemina Tablets (levonorgestrel - ethinylestradiol compound formulation): Nobelpharma/ASKA Pharmaceutical
    • 12.3.1. Product Description
    • 12.3.2. Regulatory Milestones
  • 12.4. Visanne (Dinagest): Mochida/Bayer Schering Pharma AG
    • 12.4.1. Product Description
    • 12.4.2. Regulatory Milestones
    • 12.4.3. Other Developmental Activities
    • 12.4.4. Pivotal Clinical Trials

13. Emerging Therapies

  • 13.1. Yselty (Linzagolix; OBE2109): ObsEva
    • 13.1.1. Product Description
    • 13.1.2. Other Developmental Activities
    • 13.1.3. Clinical Development
    • 13.1.4. Safety and Efficacy
  • 13.2. Relugolix (TAK-385): Myovant Sciences/Takeda
    • 13.2.1. Product Description
    • 13.2.2. Other Developmental Activities
    • 13.2.3. Clinical Development
    • 13.2.4. Safety and Efficacy
  • 13.3. Pure Femme Tablets: Pure Green
    • 13.3.1. Product Description
    • 13.3.2. Other Developmental Activities
    • 13.3.3. Clinical Development
  • 13.4. FSN-013 (Estetrol/ Drospirenone): Fuji Pharma
    • 13.4.1. Product Description
    • 13.4.2. Other Developmental Activities
    • 13.4.3. Clinical Development
    • 13.4.4. Safety and Efficacy
  • 13.5. NS-580: Nippon Shinyaku
    • 13.5.1. Product Description
    • 13.5.2. Clinical Development

14. Conjoint Analysis of Dysmenorrhea Therapies

15. Dysmenorrhea: Seven Major Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Outlook

16. 7MM Market Size

  • 16.1. Total Market Size of Dysmenorrhea in the 7MM
  • 16.2. Total Market size of Dysmenorrhea by Therapies in the 7MM

17. United States Market Size

  • 17.1. Total Market size of Dysmenorrhea in the United States

18. EU-5 Market Size

  • 18.1. Germany Market Size
    • 18.1.1. Total Market size of Dysmenorrhea in Germany
  • 18.2. France Market Size
    • 18.2.1. Total Market size of Dysmenorrhea in France
  • 18.3. Italy Market Size
    • 18.3.1. Total Market size of Dysmenorrhea in Italy
  • 18.4. Spain Market Size
    • 18.4.1. Total Market size of Dysmenorrhea in Spain
  • 18.5. United Kingdom Market Size
    • 18.5.1. Total Market size of Dysmenorrhea in the United Kingdom

19. Japan Market Size

  • 19.1. Total Market size of Dysmenorrhea in Japan

20. Market Access and Reimbursement of Dysmenorrhea Therapies

21. Market Drivers

22. Market Barriers

23. Appendix

  • 23.1. Bibliography
  • 23.2. Report Methodology
  • 23.3. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

Back to Top
전화 문의
F A Q